Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 2/20 | 0.40 |
| ▸ | GRM5 | P41594 | 8/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.36 |
| ▸ | LDHA | P00338 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CDK7 | P50613 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19510918 | 0.97 | FFAR4 (0.39) | CDK4GRM5PDGFRBPDGFRAFFAR4 | |
| SCHEMBL9309427 | 0.81 | PDGFRB (0.41) | PDGFRBPDGFRALRRK2PTGS1CDK1 | |
| SCHEMBL19899744 | 0.79 | FFAR4 (0.41) | CDK4GRM5PDGFRBPDGFRAFFAR4 | |
| SCHEMBL11788449 | 0.78 | GRM5 (0.42) | CDK4GRM5PDGFRBPDGFRAFFAR4 | |
| SCHEMBL19862428 | 0.77 | CDK4 (0.41) | CDK4GRM5PDGFRBPDGFRAFFAR4 | |
| SCHEMBL3408536 | 0.76 | ALDH1A1 (0.45) | GRM5PDGFRBPDGFRAFFAR4LRRK2 | |
| SCHEMBL15662450 | 0.76 | PTGS1 (0.53) | PDGFRBPDGFRAPTGS1LMNA | |
| SCHEMBL26618046 | 0.76 | PDE2A (0.39) | CDK4GRM5PDGFRBPDGFRAFFAR4 | |
| SCHEMBL31426424 | 0.76 | PDE2A (0.39) | CDK4GRM5PDGFRBPDGFRAFFAR4 | |
| SCHEMBL23790497 | 0.75 | LRRK2 (0.44) | CDK4GRM5PDGFRBPDGFRAFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2023-11-02 | — | — | US | disclosed |
| US-11767334-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2023-09-26 | — | — | US | disclosed |
| US-20170342094-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2017-11-30 | — | — | US | disclosed |
| US-9777024-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2017-10-03 | — | — | US | disclosed |
| US-20160137672-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2016-05-19 | — | — | US | disclosed |
| US-9221843-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150119362-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2015-04-30 | — | — | US | disclosed |
| US-8962834-B2 | Modulators of amyloid beta | HOFFMANN-LA ROCHE INC. (US) | 2015-02-24 | — | — | US | disclosed |
| EP-2257541-B1 | MODULATORS FOR AMYLOID BETA | HOFFMANN LA ROCHE (CH) | 2013-08-14 | — | — | EP | disclosed |
| US-20130190302-A1 | MODULATORS OF AMYLOID BETA | HOFFMANN-LA ROCHE INC. (US) | 2013-07-25 | — | — | US | disclosed |
| CN-101952275-A | Modulators for amyloid beta | HOFFMANN LA ROCHE | 2011-01-19 | — | — | CN | disclosed |
| EP-2257541-A1 | MODULATORS FOR AMYLOID BETA | F. Hoffmann-La Roche AG (CH) | 2010-12-08 | — | — | EP | disclosed |
| US-20090215759-A1 | MODULATORS FOR AMYLOID BETA | HOFFMANN-LA ROCHE, INC. | 2009-08-27 | — | — | US | disclosed |
| WO-2009103652-A1 | MODULATORS FOR AMYLOID BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119362-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | CDK4 1099/4885GRM5 2313/4885PDGFRB 1055/4885 |
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | CDK4 1161/4885GRM5 2645/4885PDGFRB 465/4885 |
| US-20170342094-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | CDK4 1161/4885GRM5 2645/4885PDGFRB 465/4885 |
| US-11767334-B2 | Heteroaryl inhibitors of PDE4 | PDE4A, PDE4B, PDE4C | CDK4 1161/4885GRM5 2645/4885PDGFRB 465/4885 |
| US-20090215759-A1 | MODULATORS FOR AMYLOID BETA | APP, PSEN1, APOB | CDK4 4776/4885GRM5 4105/4885PDGFRB 992/4885 |
| US-20130190302-A1 | MODULATORS OF AMYLOID BETA | APP, PSEN1, APOB | CDK4 4792/4885GRM5 4213/4885PDGFRB 1047/4885 |
| US-20160137672-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | CDK4 1099/4885GRM5 2313/4885PDGFRB 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.